The Nomination Committee proposes that Genovis should expand its Board of Directors at the 2021 Annual General Meeting and proposes Steve Jordan to be elected as a new board member.
Steve Jordan was born in 1953 and resides in the United Kingdom. He is currently working as a consultant for several companies engaged in development of new novel technologies and materials for the life science industries. Previous experiences include i.a. Chief Scientific Officer and Senior Director R&D Chemistry at Biotage during the years 2005-2020. Prior to that, Head of Business Development at CombiPure UK, Director Analytical of sciences, compound management and instrument development at Millennium UK and Section Leader for High Throughput Medicinal Chemistry at Roche Discovery Welwyn. Steve has no other board assignments and is independent in relation to the company, company management and the company's major shareholders.
The new Board of Directors in the proposal to the AGM is as follows: Re-election of Torben Jørgensen, Lotta Ljungqvist, Mikael Lönn and Kenth Petersson and new election of Steve Jordan.
The Nomination Committee proposes re-election of Torben Jørgensen to serve as Chairman of the Board.
Genovis' Nomination Committee:
Mikael Lönn (Chairman)
TIN Fonder, represented by Erik Sprinchorn, Portfolio manager
Andra AP-fonden, represented by Johan Sjöström, Portfolio manager
Aktia Fondbolag AB, represented by Markus Lindqvist, Director, Aktia Kapitalförvaltning AB